神经生物标记市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球神经生物标记市场价值为 87 亿美元，预计在预测期内将经历大幅增长，到 2030 年的复合年增长率为 8.10%。神经生物标记是诊断、监测和研究中枢神经系统和周边神经系统的神经系统疾病的重要工具。近年来，市场经历了显着的成长，其驱动因素包括生物标记在现代医学和研究中的关键作用。受神经系统疾病盛行率不断上升、生物标记发现和验证的进步以及老龄化人口日益增长的影响，该行业预计将继续扩张。随着神经系统疾病变得越来越普遍，对早期、准确诊断工具的需求激增，从而推动了市场成长。

主要市场驱动因素

神经系统疾病盛行率不断上升

主要市场挑战

神经系统疾病的复杂性

主要市场趋势

个性化医疗的兴起

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：神经生物标记市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（影像、蛋白质体学、基因体学、代谢体学、其他）
  • 依应用分类（多发性硬化症、阿兹海默症、自闭症谱系障碍、帕金森氏症等）
  • 按最终使用者（研究机构、医院及医院实验室、独立临床诊断中心等）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美神经生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲神经生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区神经生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲神经生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲神经生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球神经生物标记市场：SWOT 分析

第 14 章：竞争格局

• PERKINELMER INC.
• Abbott Laboratories Inc
• Thermo Fisher Scientific, Inc.
• Banyan Biomarkers, Inc.
• Bio-Rad Laboratories, Inc.
• F. HOFFMANN-LA ROCHE LTD.
• Merck & Co., Inc.
• DiaGenic ASA
• Johnson & Johnson Services, Inc.
• Myriad Genetics, Inc

第 15 章：策略建议

第16章 调査会社について・免责事项

The Global Neurological Biomarkers Market was valued at USD 8.70 billion in 2024 and is projected to experience substantial growth during the forecast period, with a CAGR of 8.10% through 2030. This market represents a dynamic and rapidly advancing segment within the healthcare and life sciences industry. Neurological biomarkers are essential tools used for diagnosing, monitoring, and researching neurological disorders that affect both the central and peripheral nervous systems. The market has experienced significant growth in recent years, driven by factors that highlight the critical role of biomarkers in modern medicine and research. The sector is expected to continue its expansion, influenced by increasing prevalence of neurological disorders, advances in biomarker discovery and validation, and a growing aging population. As neurological conditions become more widespread, the demand for early, accurate diagnostic tools has surged, fueling market growth.

Key Market Drivers

Increasing Prevalence of Neurological Disorders

The growing incidence of neurological disorders globally plays a significant role in shaping the Neurological Biomarkers Market. As conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, and traumatic brain injuries become more common, the need for advanced diagnostic tools, early detection methods, and precision treatment solutions has risen. Neurological biomarkers are critical in meeting these needs and driving market growth. These disorders are major contributors to disability and mortality worldwide, affecting over one in three individuals. In 2021, stroke was identified as the leading cause of health loss among the top neurological conditions. This rising disease burden has emphasized the need for early and accurate diagnostic solutions, thereby increasing the demand for neurological biomarkers.

The global aging population has resulted in an increase in neurodegenerative diseases, particularly Alzheimer's. The global dementia population is expected to nearly double every 20 years, reaching 78 million by 2030 and 139 million by 2050. A large proportion of this growth is expected in developing countries, where dementia prevalence is rapidly rising. Currently, 60% of dementia cases occur in low- and middle-income nations, with this figure projected to rise to 71% by 2050, underscoring the urgent need for expanded healthcare infrastructure, diagnostic capabilities, and intervention strategies in these regions. Biomarkers are increasingly incorporated into diagnostic protocols to detect Alzheimer's at early or pre-symptomatic stages.

In the United States, approximately one million individuals are diagnosed with Parkinson's disease (PD), and this number is expected to increase to 1.2 million by 2030. As the second most prevalent neurodegenerative disorder after Alzheimer's, Parkinson's presents a growing public health challenge, driving demand for advanced diagnostics, early detection, and innovative treatment solutions. Additionally, approximately one in four adults worldwide is at risk of experiencing a stroke, with over 12 million individuals expected to have their first stroke this year, leading to an anticipated 6.5 million fatalities. More than 100 million people globally are living with the long-term effects of stroke, highlighting the urgent need for improved prevention, early detection, and treatment options. Neurological biomarkers such as glial fibrillary acidic protein (GFAP) and S100B are widely used in stroke detection and brain injury assessment, further driving market growth. As more healthcare providers adopt biomarker-based diagnostic tests, the market continues to expand.

Key Market Challenges

Complexity of Neurological Disorders

A significant challenge in the development and adoption of neurological biomarkers is the complexity of neurological disorders. These conditions span a wide range of diseases, each with its unique characteristics and mechanisms. Disorders such as Alzheimer's, Parkinson's, and multiple sclerosis exhibit considerable heterogeneity among patients, making it difficult to identify universal biomarkers applicable to all cases. This complexity necessitates the discovery and validation of diverse biomarkers, a process that can be both time-consuming and resource-intensive. Furthermore, the concept of precision medicine, which tailors treatment to individual patients based on their unique biomarker profiles, complicates the development of standardized biomarkers. Customized biomarker panels may be required for each patient, increasing the need for personalized medicine approaches.

Key Market Trends

Rise of Personalized Medicine

A key trend in the Global Neurological Biomarkers Market is the shift toward personalized medicine, which involves tailoring medical treatments to individual patients based on their genetic, biomarker, and clinical profiles. This trend is fueled by advances in genomics and biomarker technologies, which allow for more precise disease predictions and treatment planning. The sequencing of the human genome, along with high-throughput genomics technologies, has enabled the identification of genetic variations associated with neurological disorders. These genetic biomarkers are used to assess disease risk and develop personalized treatment strategies. Additionally, biomarker panels that incorporate genetic, proteomic, and imaging data are being developed to provide more accurate diagnoses and differentiate between various subtypes of neurological disorders.

Personalized medicine enhances treatment effectiveness by selecting therapies that are most likely to work for individual patients, thereby minimizing the risk of adverse effects and optimizing therapeutic outcomes.

Key Market Players

• PerkinElmer Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Banyan Biomarkers Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• DiaGenic ASA
• Johnson & Johnson Services Inc.
• Myriad Genetics Inc.

Report Scope

This report segments the Global Neurological Biomarkers Market into the following categories, in addition to detailing the industry trends:

Neurological Biomarkers Market, by Type:

• Imaging
• Proteomic
• Genomic
• Metabolomic
• Others

Neurological Biomarkers Market, by Application:

• Multiple Sclerosis
• Alzheimer's Disease
• Autism Spectrum Disorder
• Parkinson's Disease
• Others

Neurological Biomarkers Market, by End-User:

• Research Organizations
• Hospitals and Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Others

Neurological Biomarkers Market, by Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report includes detailed company profiles of the major players in the Global Neurological Biomarkers Market.

Available Customizations:

This report on the Global Neurological Biomarkers Market includes customized options to cater to a company's specific needs. The following customizations are available:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Neurological Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Imaging, Proteomic, Genomic, Metabolomic, Others)
  • 5.2.2. By Application (Multiple Sclerosis, Alzheimer's Disease, Autism Spectrum Disorder, Parkinson's Disease, Others)
  • 5.2.3. By End-User (Research Organizations, Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Neurological Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neurological Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Neurological Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Neurological Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Neurological Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neurological Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Neurological Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Neurological Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Neurological Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Neurological Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Neurological Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neurological Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Neurological Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Neurological Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Neurological Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Neurological Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Neurological Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neurological Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Neurological Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Neurological Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Neurological Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neurological Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Neurological Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Neurological Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neurological Biomarkers Market: SWOT Analysis

14. Competitive Landscape

• 14.1. PERKINELMER INC.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Abbott Laboratories Inc
• 14.3. Thermo Fisher Scientific, Inc.
• 14.4. Banyan Biomarkers, Inc.
• 14.5. Bio-Rad Laboratories, Inc.
• 14.6. F. HOFFMANN-LA ROCHE LTD.
• 14.7. Merck & Co., Inc.
• 14.8. DiaGenic ASA
• 14.9. Johnson & Johnson Services, Inc.
• 14.10.Myriad Genetics, Inc

15. Strategic Recommendations

16. About Us & Disclaimer